Mateusz Legut

Mateusz Legut

2013-Present: Cancer Research UK-funded 4 year PhD programme.

My project focuses on discovery of novel cancer antigens recognised by non-conventional (e.g. non-MHC restricted) T cells, such as γδ T cells. These cells constitute a minor fraction of peripheral blood T cells but can efficiently infiltrate diverse tumours, most notably melanoma. Some of them respond to multiple tumour types but the identity of the ligands they recognise remains largely unknown. Description on new, broadly recognised γδ T cell antigens, which is the aim of my project, could potentially be translated into off-the-shelf immunotherapies applicable to cancer patients regardless of their MHC type.

2010-2013: Bachelor of Science (1st class) in Biotechnology, University of Wroclaw (Wroclaw, Poland).

My thesis project involved designing novel liposomal delivery systems for anthracyclines combined with an epigenetic modulator as a potential treatment for breast cancer and melanoma. During my 1st degree I had also an opportunity to attend a summer internship at the University Medical Centre Groningen (Groningen, Netherlands) where I was working on targeted delivery of novel anti-inflammatory drugs (EBVDT group, Dr J. Kamps’ lab).


Legut, M., Lipka, D., Filipczak, N., Piwoni, A., Kozubek, A., and Gubernator, J. (2014). Anacardic acid enhances the anticancer activity of liposomal mitoxantrone towards melanoma cell lines - in vitro studies. Int. J. Nanomedicine 9, 653–668.

Lipka, D., Gubernator, J., Filipczak, N., Barnert, S., Süss, R., Legut, M., and Kozubek, A. (2013). Vitamin C-driven epirubicin loading into liposomes. Int. J. Nanomedicine 8, 3573–3585.